Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
ATRA has been the subject of a number of other reports. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price target on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $47.80.
NASDAQ ATRA opened at $38.00 on Friday. The company has a market capitalization of $1.43 billion, a PE ratio of -9.50 and a beta of 2.54. Atara Biotherapeutics has a 52-week low of $12.65 and a 52-week high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.17). As a group, research analysts anticipate that Atara Biotherapeutics will post -4.58 EPS for the current fiscal year.
In related news, CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $37.43, for a total transaction of $291,954.00. Following the transaction, the chief executive officer now owns 812,613 shares of the company’s stock, valued at $30,416,104.59. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 3,900 shares of the firm’s stock in a transaction that occurred on Monday, October 22nd. The shares were sold at an average price of $33.78, for a total transaction of $131,742.00. Following the transaction, the chief executive officer now directly owns 733,285 shares in the company, valued at approximately $24,770,367.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,675 shares of company stock worth $3,106,590. Insiders own 10.60% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of ATRA. Great West Life Assurance Co. Can raised its position in shares of Atara Biotherapeutics by 100.1% in the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 1,655 shares during the period. Bank of Montreal Can bought a new position in shares of Atara Biotherapeutics in the second quarter valued at approximately $180,000. Principal Financial Group Inc. bought a new position in shares of Atara Biotherapeutics in the first quarter valued at approximately $214,000. Highland Private Wealth Management bought a new position in shares of Atara Biotherapeutics in the second quarter valued at approximately $202,000. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Atara Biotherapeutics in the third quarter valued at approximately $244,000.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Article: Cost of Debt
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.